AUPH
NASDAQ HealthcareAurinia Pharmaceuticals Inc - Common Shares
Biotechnology
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
๐ Market Data
| Price | $15.94 |
|---|---|
| Volume | 829,882 |
| Market Cap | 2.05B |
| Beta | 1.420 |
| RSI (14-Day) | 33.6 |
| 200-Day MA | $14.94 |
| 50-Day MA | $16.02 |
| 52-Week High | $19.25 |
| 52-Week Low | $8.55 |
| P/E Ratio | 7.38 |
| Forward P/E | 14.26 |
| Price / Book | 3.67 |
๐ฏ Investment Strategy Scores
AUPH scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (86/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ Over-Hyped (11/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find AUPH in your text
Paste any article, transcript, or post โ the tool will extract AUPH and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.